QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

NCT05799820 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

DRUG: QL1706
DRUG: Bevacizumab
DRUG: Oxaliplatin injection
DRUG: Capecitabine

Sponsor

Qilu Pharmaceutical Co., Ltd.